Log in

OTCMKTS:WINTWindtree Therapeutics Stock Price, Forecast & News

$6.82
-0.17 (-2.43 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.80
Now: $6.82
$7.05
50-Day Range
$6.25
MA: $7.12
$7.80
52-Week Range
$4.00
Now: $6.82
$14.97
Volume19,500 shs
Average Volume14,762 shs
Market Capitalization$93.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32
Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Read More
Windtree Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:WINT
Previous SymbolNASDAQ:WINT
CUSIP25466840
Phone215-488-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$200,000.00
Book Value$5.12 per share

Profitability

Net Income$-27,480,000.00

Miscellaneous

Employees27
Market Cap$93.41 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions

How has Windtree Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Windtree Therapeutics' stock was trading at $3.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, WINT shares have increased by 84.3% and is now trading at $6.82. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Windtree Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Windtree Therapeutics.

When is Windtree Therapeutics' next earnings date?

Windtree Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Windtree Therapeutics.

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (OTCMKTS:WINT) released its quarterly earnings results on Thursday, May, 14th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter. View Windtree Therapeutics' earnings history.

When did Windtree Therapeutics' stock split? How did Windtree Therapeutics' stock split work?

Shares of Windtree Therapeutics reverse split on the morning of Wednesday, April 29th 2020. The 1-3 reverse split was announced on Tuesday, April 28th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 28th 2020. An investor that had 100 shares of Windtree Therapeutics stock prior to the reverse split would have 33 shares after the split.

What price target have analysts set for WINT?

1 brokerages have issued twelve-month target prices for Windtree Therapeutics' stock. Their forecasts range from $12.25 to $12.25. On average, they anticipate Windtree Therapeutics' share price to reach $12.25 in the next year. This suggests a possible upside of 79.6% from the stock's current price. View analysts' price targets for Windtree Therapeutics.

Has Windtree Therapeutics been receiving favorable news coverage?

Media headlines about WINT stock have trended somewhat negative on Saturday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Windtree Therapeutics earned a daily sentiment score of -1.8 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Windtree Therapeutics.

Who are some of Windtree Therapeutics' key competitors?

What other stocks do shareholders of Windtree Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Windtree Therapeutics investors own include La Jolla Pharmaceutical (LJPC), Trevena (TRVN), NovaBay Pharmaceuticals (NBY), XOMA (XOMA), CTI BioPharma (CTIC), Reshape Lifesciences (RSLS), CorMedix (CRMD), Microbot Medical (MBOT), Novavax (NVAX) and SLS International (SLS).

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the following people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 54)
  • Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 60)
  • Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 67)
  • Ms. Mary B. Templeton, Sr. VP, Gen. Counsel & Corp. Sec. (Age 72)

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $6.82.

How big of a company is Windtree Therapeutics?

Windtree Therapeutics has a market capitalization of $93.41 million and generates $200,000.00 in revenue each year. Windtree Therapeutics employs 27 workers across the globe.

What is Windtree Therapeutics' official website?

The official website for Windtree Therapeutics is www.windtreetx.com.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.